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Abstract
Background: Evidence of the chemopreventive effects of the
dietary antioxidants A-tocopherol (vitamin E) and L-seleno-
methionine (selenium) comes from secondary analysis of two
phase III clinical trials that found treatment with these
antioxidants reduced the incidence of prostate cancer. To
determine the effects of selenium and vitamin E in blood and
prostate tissue, we undertook a preoperative feasibility study
complementary to the currently ongoing Selenium and
Vitamin E Cancer Prevention Trial.
Methods: Forty-eight patients with clinically localized pros-
tate cancer enrolled on this 2  2 factorial design study were
randomized to take selenium, vitamin E, both, or placebo for
3 to 6 weeks before prostatectomy. Sera were collected from
patients before and after dietary supplementation. Thirty-
nine patients were evaluable, and 29 age-matched disease-
free men served as controls. Mass profiling of lipophilic
serum proteins of lower molecular weight (2-13.5 kDa) was
conducted, and mass spectra data were analyzed using
custom-designed software.
Results: Weighted voting analyses showed a change in sera
classification from cancerous to healthy for some patients
with prostate cancer after dietary intervention. ANOVA
analysis showed significantly different treatment effects on
prediction strength changes among the four groups at a 95%
confidence level. Eliminating an outlying value and
performing post hoc analysis using Fisher’s least significant
difference method showed that effects in the group treated
with the combination were significantly different from those
of the other groups.
Conclusion: In sera from patients with prostate cancer,
selenium and vitamin E combined induced statistically
significant proteomic pattern changes associated with pros-
tate cancer–free status. (Cancer Epidemiol Biomarkers Prev
2005;14(7):1697–702)
Introduction
No reliable and sensitive method currently exists to diagnose
prostate cancer or to monitor therapeutic interventions to treat
it. Despite the widespread clinical use of the serum prostate–
specific antigen test, it is neither sufficiently sensitive nor
specific for early detection of prostate cancer, and it is not
predictive of biological behavior of tumors (1-3). Because of the
inherent heterogeneity of prostate tumors, it is likely that a
panel of proteins could serve better than the prostate-specific
antigen as ‘‘signatures’’ for modulation of the molecular and
cellular events occurring during carcinogenesis and therapeu-
tic intervention. In fact, studies in several different tumor
types, including prostate, brain, gastrointestinal, breast, ovar-
ian, and hepatocellular cancers, have shown that serum
protein patterns could be used to differentiate cancer from
controls (4-9). Proteomics, because it considers all serologic
proteins, could potentially identify multiple biomarkers
instead of only one. Although none of these proteins alone
merits total reliance, together their profiling pattern, assisted
by statistical analyses, could yield a quick and reliable
diagnosis of prostate cancer (4, 10, 11). Furthermore, this
qualitative approach is able to reveal the molecular and
cellular effects of therapeutic or dietary intervention in a
period as short as several weeks.
Selenium and vitamin E are important intracellular anti-
oxidants, but their function in preventing prostate cancer was
initially discovered in studies intended to investigate their
chemopreventive role in other cancers. Selenium’s effect on
prostate cancer, for example, was found during a study of its
effects on skin cancer (12). In a randomized controlled study,
1,312 patients with skin cancer were given 200 Ag of selenium
orally (in the form of selenized yeast) or placebo daily. The
study did not find that selenium treatment protected against
the development of skin cancer, but a secondary analysis of the
results revealed a 63% reduction of prostate cancer in patients
treated with selenium. In an update from the Nutritional
Prevention of Cancer trial, investigators reported finding a
continued protective effect by supplemental selenium in data
through the end of the blinded treatment in 1996. Selenium
reduced the overall incidence of prostate cancer by 49%, albeit
the effect was limited to patients with lower baseline prostate-
specific antigen and plasma selenium concentrations (<123.2
ng/mL; ref. 13).
Likewise, findings of the chemopreventive effects of
vitamin E (a-tocopherol) were also from secondary analysis
of another study. The a-tocopherol, h-carotene study, which
evaluated 29,133 male smokers between 50 and 69 years of
age from southwestern Finland, was initially designed to find
vitamin E’s chemopreventive effect against lung cancer as
measured in incidence. Results showed no reduction in lung
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cancer incidence after 5 to 8 years of dietary supplementation
of a-tocopherol or h-carotene (14); however, a secondary
study of the 6-year follow-up showed a significant reduction
in prostate cancer incidence among participants treated with
vitamin E. Inasmuch as these studies were initially designed
for lung and skin cancer, findings related to prostate cancer
must be treated with caution. However, a prospective
randomized clinical trial with reduction in the incidence of
prostate cancer as an a priori hypothesis is still needed to
evaluate the role of vitamin E and selenium as chemo-
preventive agents for prostate cancer.
In 2001, a phase III chemoprevention trial in prostate
cancer—the Selenium and Vitamin E Cancer Prevention Trial
(SELECT)—was initiated. The primary end point of SELECT
is the detection of a 25% reduction in the incidence of
prostate cancer for selenium or vitamin E alone with an
additional 25% decrease for the combination. This multicen-
ter, randomized, placebo-controlled, double-blind, phase III
trial of supplemental selenium and vitamin E is expected to
enroll >32,000 men over 7 to 15 years. Creating a comple-
mentary trial employing the identical formulations of
selenium and vitamin E, we undertook a preprostatectomy
placebo–controlled feasibility study to determine the biologic
effects of these agents in blood and prostate tissue. Using
serum samples from 39 patients evaluable for blood
biomarker correlative study and 29 healthy controls, we
examined whether differential serum proteomic patterns
could be induced by short-term antioxidant supplementation.
Materials and Methods
Patients. Forty-eight presurgical patients with clinically
organ-confined prostate cancer at The University of Texas
M.D. Anderson Cancer Center in Houston were enrolled in a
randomized, double-blind trial of vitamin E and selenium
between February 2001 and April 2002. Twenty-nine age-
matched men, who consented to participate at the University
of Massachusetts, served as prostate cancer–free controls,
providing serum samples but receiving no treatment. The
protocol and informed consent forms were approved by the
respective universities’ Institutional Review Boards, and an
informed consent form was signed by all patients and controls
before participation.
Eligibility criteria required patients to have clinical stage
T1c/T2 disease, a prostate-specific antigen level <10 ng/mL
within 3 months of study registration, a Gleason score V7, and
a prostatectomy scheduled 3 to 6 weeks after the start of
treatment. Patients taking >50 Ag of selenium and/or z300 IU
of vitamin E over 3 consecutive days within 1 month of
registration were excluded. Once enrolled, patients received
400 IU of vitamin E (all rac a-tocopheryl acetate), 200 Ag of
selenium (L-selenomethionine), a combination of vitamin E
and selenium, or placebo daily for 3 to 6 weeks. The
formulations of selenium and vitamin E were the same as
those in the ongoing SELECT. Each patient also received a
multivitamin and 250 mg of vitamin C daily. Each multivita-
min contained high-selenium yeast (30 Ag) and D-a-tocopherol
(30 IU), contributing to incremental increases in supplemental
selenium and vitamin E of 15% and 7.5%, respectively. Serum
samples were collected from the patients before and after
treatment.
Proteomics Analysis. The venous blood samples were
collected in serum separator tubes from patients participating
in the study at M.D. Anderson before and after treatment.
The samples were initially allowed to clot at room temper-
ature and then were centrifuged to separate the cellular
component from the supernatant within 2 hours of collection.
Aliquots of supernatant were promptly frozen and stored at
80jC until analyzed. The samples were archived for 11 to 26
months. The samples from the 29 prostate cancer–free
controls from the University of Massachusetts were processed
following similar standard procedures. These control samples
were archived at 80jC for 1 to 12 months until analyzed.
All samples for the training set were analyzed at the same
time, and none of the samples were discarded on the basis of
turbidity or hemolysis. All samples used in the experiment
were thawed only once.
Lipophilic proteins/peptides were extracted from each
serum sample with UltraMicroSpin C18 columns (The Nest
Group, Southboro, MA) following a previously published
protocol (4). In brief, sera were diluted by mixing 4 AL crude
serum of each sample with 200 AL solution containing 5%
acetonitrile (MeCN) and 1% trifluoroacetic acid, which was in
turn passed through the C18 column and washed thrice with
50 AL of the 5% MeCN/1% trifluoroacetic acid solution. The
mixture was finally eluted with 30 AL of 75% MeCN/1%
trifluoroacetic acid solution. Each washing and elution cycle
was done by centrifugation at 2,500  g . Five microliters of the
final eluted solution were mixed with an equal volume of 50%
saturated matrix, consisting of sinapic acid in 50:50 5% MeCN/
1% trifluoroacetic acid (4).
All data were obtained using the Ciphergen Protein
Biosystem II with delayed extraction in conjunction with
Ciphergen 2.1 software. The dried droplet method was used to
crystallize 1 AL of the matrix/sample mixture on a blank
sample probe (4). An automatic protocol was designed to
accomplish the data collection.
The variables for the protocol were set as follows: the mass
window was set to acquire data from 0 to 20 kDa and was
optimized between 3 and 10 kDa, yielding an extraction time
delay of 600 ns. Each mass spectrum is the result of averaging
200 optimal shots. The intensity of the UV nitrogen laser (337
nm) was set at 240 V, the filter average was set to 0.2 times the
expected peak width, and the baseline smoothing was set to 25
points before baseline correction. On the day of the experi-
ment, external calibration was carried out with the following
protein standards: [M + 1]+ and [M + 2]+ peaks from each
standard-bovine insulin (5,733.6), bovine ubiquitin (8,564.8),
and bovine cytochrome c (12,230.9). An internal calibration
was completed with a combination of external protein stand-
ards and the extracted serum proteins in order to mark
proteins found in each patient sample that encompassed the
range of molecular weights of interest. In this way, each
spectrum was internally calibrated with endogenous proteins
present in each sample.
Data Processing and Analysis. Using Peakfit version 4.0 to
perform the processing, we narrowed the mass spectra
frame to capture data between 2 and 13.5 kDa, eliminating
data that, from our experience, do not play a significant role
in the prediction strength calculation. We then smoothed the
spectra display data with a Gaussian convolute algorithm,
adjusted background using a second derivative zero tech-
nique, normalized the spectra to 1.0, and zeroed the negative
data. The processed mass spectra data were then exported to
a text file.
The resulting text file was in turn imported into the data-
processing application software MOCS,8 which had been
custom-designed and implemented for the weighted voting
method. MOCS did all the necessary subsequent steps in the
analysis automatically with the input of several variables.
First, MOCS lined up the data points from all smoothed
and normalized spectra against a single mass-to-charge (M/Z)
value array, which was calculated to the mass accuracy of the
internally calibrated spectra of 150 ppm. The aligned data
8 Modulized Classification System, Sun and Ho, unpublished.
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were further standardized to set all intensity values between
0 and 1. The standardization was done using the equation
Sstandardized ¼ ðSx  SminÞ=ðSmax  SminÞ;
where Sx is the data point that needs to be standardized, Smin
is the lowest intensity of all spectra for the M/Z value, and
Smax is the highest intensity of all spectra for this M/Z value.
By using this standardization strategy (4), we gave all
intensities equal significance.
The standardized spectra data contained the intensity of all
M/Z values from 2 to 13.5 kDa. We optimized the training set
data and chose the top 1,000 M/Z values that had the most
influence on the clustering. To determine the top 1,000 M/Z
values, we calculated the weighted value for each M/Z . The
training set consisted of two groups: pretreatment samples
from 39 men who had prostate cancer and samples from the 29
controls who did not have prostate cancer. Those M/Z values
with larger distances between the means of intensity of the two
groups and smaller SDs within each group were granted
values of higher weight. The equation used to calculate the
weighted value, WM/Z , was
WM=Z ¼ ðMh McÞ=ðdh þ dcÞ;
where Mh is the mean of the healthy group, Mc is the mean of
the group with prostate cancer, dh is the SD of the healthy
group, and dc is the SD of the group with prostate cancer (15).
This way, the M/Zs with the most significant values
differentiating serum of those with prostate cancer from serum
of controls have the highest weights.
The 1,000 M/Zs with the highest weighted values were
selected and used for comparison against the posttreatment
samples in the weighted voting analysis. For each of the
posttreatment samples, the training set voted on each of the
1,000 top-weighted M/Z values using the equation,
VM=Z ¼ WM=Zf½ðSstandardized MallÞ=dall	  BM=Zg;
where WM/Z is the weighted value for M/Z , Sstandardized is the
standardized intensity value of the posttreatment sample at the
M/Z value, Mall is the mean of all training set values at this M/
Z , and BM/Z is the statistically derived border of this M/Z (15),
defined as
BM=Z þ ðMh þMcÞ=2;
where Mh is the mean of all samples in the healthy group and
Mc is the mean of all samples in the group with prostate
cancer. In this study, a positive vote indicated that at this M/Z
value, the training set classified the sample into the group
associated with being disease-free, whereas a negative vote
classified the sample into the group associated with having
prostate cancer. The resulting vote (VM/Z) for each of the 1,000
M/Z values was used to calculate the sum of all positive votes
(Vp) and the sum of all negative votes (Vn), respectively. A
larger absolute value of Vp classified the sample into the group
associated with being disease-free, and a larger absolute value
of Vn classified the sample into the group associated with
having prostate cancer. To describe the chance that the
classification was accurate, we used a variable called predic-
tion strength as a quantitative measurement (4, 15). The
prediction strength is calculated with the equation
PS ¼ ðjVpj  jVnjÞ=ðjVpj þ jVnjÞ:
The prediction strength values range from 1 to 1. A positive
prediction strength value is associated with being disease-free,
and a negative value is associated with having prostate cancer.
The closer the value is to 0 (the border of the two groups), the
less chance that the classification is accurate; the closer it is to
either 1 or 1, the more likely that classification is accurate. An
arbitrary cutoff can be set to exclude certain samples. Setting
such a cutoff increases the reliability of the prediction at the cost
of lowered usability, because with this method, more samples
fall into the category of nonclassifiable. In our study, no
arbitrary cutoff value was applied; thus, any sample with a
positive prediction strength value was classifiable as disease-
free, and any sample with a negative prediction strength value
was classifiable as prostate cancer.
Prediction strength values that resulted from weighted
voting were calculated for the patients before and after the
dietary supplementation treatment. The changes in the
prediction strength values after the dietary supplementation
were calculated for each sample, and the data set was analyzed
using one-way ANOVA and Fisher’s least significant differ-
ence method. Compared with other samples in the placebo
group, sample 9 had an unusually high prediction strength
value change toward the positive direction. It contributed
49.5% of the total statistical significance in the ANOVA
analysis and lay outside the 95% confidence interval of the
samples in the placebo group. In line with common practice,
this outlier was excluded from the final analysis of the data set.
Results
Prediction strength values determined after weighted voting
analyses showed that before dietary supplementation, most
serum samples from the patients with prostate cancer had
negative prediction strength values, values that are asso-
ciated with prostate cancer (Table 1; Fig. 1). However, after
dietary supplementation, many of the serum sample values
obtained from patients given the combination were positive
prediction strength values, which are commonly associated
with the absence of disease (Fig. 2). Generally speaking, the
closer the prediction strength value to 1 or 1, the more
likely that the classification is correct.
ANOVA analysis on the entire data set (Table 2), as well as
on the set without sample 9 (Table 3), both showed significant
statistical differences in prediction strength value changes
among the four groups at the 0.05 level. Analysis on the data
without sample 9 yielded an F ratio of 3.75 (Table 3). The
probability of the result, assuming the null hypothesis (that all
diet supplement treatment had the same effects on prediction
strength change) is 0.020, which suggests that the effect on
each arm was significantly different from the others at the 0.05
level. In the post hoc analysis of data without sample 9, the
results at the 0.05 significance level using Fisher’s least
significant difference test suggest that the different treatment
methods had significantly different effects: significant differ-
ences were found between the group receiving the combina-
tion and all other three groups (Table 4). There were no
significant differences in effect among the groups which
received selenium treatment, vitamin E treatment, or the
placebo group (Table 4).
Furthermore, ANOVA evaluation indicated no significant
differences among the groups on the basis of age (F ratio =
0.638), duration of treatment (F ratio = 1.210), pretreatment
prostate-specific antigen level (F ratio = 0.630), relation to
biopsy Gleason score (F ratio = 1.085), relation to prostatecto-
my Gleason score (F ratio = 0.144), or pretreatment perfor-
mance status (F ratio = 0.256).
Discussion
Because evidence of the chemopreventive properties of
selenium and vitamin E comes from secondary analysis of
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two phase III clinical trials, researchers conducted SELECT, a
multicenter, randomized placebo-controlled, double-blind
phase III trial with reduction of the incidence of prostate cancer
as an end point. In order to use proteomics to characterize the
biological effects of these agents in blood, we used serum
samples of patients treated with the selenium and vitamin E
formulations identical to those in SELECT for 3 to 6 weeks
preprostatectomy and evaluated serum samples from 29
disease-free age-matched men as controls. Because this was a
study in preprostatectomy patients with prostate cancer in
whom the benefits of short-term intervention of antioxidants
was unknown, and because it was anticipated that recruitment
of patients to a placebo-controlled study would be difficult, we
decided to provide a multivitamin and extra vitamin C daily.
Each tablet contained high-selenium yeast (30 Ag) and D-a-
tocopherol (30 IU), contributing to incremental increases in
Table 1. Prediction strength values before and after treatment
Group Sample Pretreatment Posttreatment Prediction
strength change
Selenium 1 0.506 0.7037 0.1977
Selenium 5 0.135 0.6641 0.5291
Selenium 6 0.086 0.1523 0.0663
Selenium 13 0.271 0.2929 0.0219
Selenium 21 0.439 0.5775 0.1385
Selenium 24 0.168 0.2246 0.0566
Selenium 30 0.300 0.5063 0.2063
Selenium 43 0.283 0.1527 0.1303
Selenium 44 0.328 0.5491 0.2211
Vitamin E 4 0.561 0.6872 0.1262
Vitamin E 7 0.796 0.8397 0.0437
Vitamin E 14 0.494 0.7966 0.3026
Vitamin E 16 0.012 0.1438 0.1318
Vitamin E 20 0.061 0.3501 0.4111
Vitamin E 27 0.396 0.4090 0.0130
Vitamin E 37 0.221 0.4709 0.2499
Vitamin E 42 0.236 0.3752 0.6112
Vitamin E 45 0.582 0.3353 0.2467
Vitamin E 47 0.408 0.3421 0.7501
Vitamin E 48 0.418 0.6344 0.2164
Combination 3 0.118 0.6887 0.5707
Combination 8 0.491 0.2928 0.1982
Combination 12 0.054 0.7378 0.7918
Combination 17 0.188 0.0020 0.1900
Combination 18 0.527 0.3199 0.2071
Combination 19 0.479 0.4450 0.9240
Combination 32 0.639 0.6158 0.0232
Combination 33 0.260 0.7674 1.0274
Combination 35 0.186 0.5728 0.3868
Combination 40 0.089 0.0998 0.0108
Placebo 2 0.140 0.5650 0.4250
Placebo 9 0.279 0.5514 0.8304
Placebo 10 0.717 0.6890 0.0280
Placebo 22 0.394 0.5777 0.1837
Placebo 25 0.278 0.6323 0.3543
Placebo 31 0.118 0.0500 0.0680
Placebo 34 0.010 0.4313 0.4413
Placebo 38 0.549 0.3776 0.1714
Placebo 46 0.065 0.3482 0.2832
Figure 1. Prediction strength values before treatment. Left to right,
selenium (black columns), vitamin E (dark gray columns), selenium
and vitamin E combination (light gray columns), and placebo (white
columns). Samples with positive prediction strength values were
classified as healthy and those with negative prediction strength
values were classified as indicative of prostate cancer. The closer
the prediction strength value was to 0, the less chance that the
classification was accurate; the closer it was to either 1 or 1, the
more likely that classification was accurate.
Figure 2. Prediction strength values after treatment. Left to right,
selenium (black columns), vitamin E (dark gray columns), selenium
and vitamin E combination (light gray columns), and placebo (white
columns); see Fig. 1 for additional information.
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supplemental selenium and vitamin E of 15% and 7.5%,
respectively. Thirty-nine of 48 patients were evaluable. Weight-
ed voting analysis of serologic protein mass profiling data
indicated a change in classification mostly in patients who had
received the selenium and vitamin E combination. These
patients’ values changed from levels associated with disease
to those associated with its absence. In post hoc analysis, the
shift in serum classification, protein profiling as quantified by
changes in prediction strength value, indicated that effects in
the groups treated with the selenium and vitamin E combina-
tion were significantly different from those of the groups
treated with selenium, vitamin E, or placebo.
The time between histologic diagnosis of prostate cancer
and definitive therapy (prostatectomy) provides an opportu-
nity to test the biological effects of chemopreventive agents
with minimal side effects. The phase II preprostatectomy
cancer prevention trials employing short interventions with
chemopreventive agents have been widely adopted, and in this
setting, proteomics provides an effective method to discover
biomarkers easily measurable in such biofluids as serum. In
this study, enrolling patients slated for prostatectomy, rather
than disease-free men as in the SELECT, was determined best
because it offered full study of the biological effects of the
study agents on the prostatectomy specimen.
Our data analysis is innovative in that, by using serologic
protein patterns to evaluate the patients’ status, potentially
many biomarkers were used and had effects on the final
results. Unlike other serologic protein mass profiling studies
clustering methods, which are usually aimed at differentiating
only two states (with cancer and without) as diagnosis results,
the use of weighted voting analysis and prediction strength
values provides a way to quantitatively describe the pattern
changes among multiple groups and, in turn, facilitates other
statistical analysis on the results, such as ANOVA and post hoc
analysis.
The lengthy and unpredictable natural history of prostate
cancer makes implementing a primary chemoprevention trial
logistically difficult. Prostate cancer tumor progression from
microscopic to metastatic disease is poorly understood.
Oxidative stress–induced genomic and mitochondrial DNA
mutations have been implicated as tumor promotion factors in
recent population studies (16, 17). Offering a viable option in
this setting is primary prevention, especially given that
prostate cancer has as long latency period (18). Although
undertaking a chemoprevention trial to evaluate a drug’s
efficacy with cancer incidence reduction as the primary end
point in prostate cancer would be both expensive and time-
consuming, it is logical to identify cellular and molecular
intermediate biomarkers in a particular mechanistic pathway
in prostate tissue or blood, which is more easily accessible.
Such intermediate biomarkers could serve as surrogate end
points for a reduction in the cancer incidence in large
randomized trials.
The post hoc analysis using protected Fisher’s least
significant difference method, which is based on the previous
rejection of the null hypothesis with F test, showed that
different dietary supplementation treatments had significantly
different effects on the groups. One sample (an extreme
outlier) was omitted under the assumption that results within
each group are normally distributed. The clinical data of this
patient was checked, and no significant difference was found
between his data and data of other patients in the group. There
exists the possibility that the patient may have taken
alternative treatment, which could have affected his prediction
strength values and skewed the range upward. Such an
extreme outlying value as his will not only affect the validity of
the test results, but also, by increasing the variability of each
group, significantly reduce test sensitivity.
The statistical analysis of serologic protein patterns pro-
duced by the mass spectrometry method yielded a quick and
direct view of the effects of dietary supplement treatment
without performing actual biopsy, a procedure with findings
that cannot be matched in quality by other available methods.
This approach, however, did not reveal details of how the
combination of selenium and vitamin E affected the mecha-
nisms of cancer progression. Furthermore, it did not correlate
changes in protein patterns to tumor grade, pretreatment
prostate-specific antigen, or treatment duration. The small
sample size in each category would prevent meaningful
analysis.
Despite efforts to ensure that the venous blood samples in
both the Massachusetts and Texas studies were collected,
processed, and stored similarly, differences in the duration of
storage occurred. Samples from patients with prostate cancer
were archived 11 to 26 months; those from cancer-free controls
were archived 1 to 12 months. Although we are unsure what, if
any, bias this difference may have introduced, it should be
acknowledged that differences in storage duration occurred
and that they may have affected the results of the study.
Having the controls at another site, although not ideal, was not
expected to affect results.
Studies using protein purification in serum and tissue
microarrays to examine selected proteins that are most affected
by the treatment are currently under way.
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